Actavis renamed as Allergan

Actavis has now changed its name to Allergan and began trading under its new moniker on the New York Stock Exchange on 15 June. The name change follows the acquisition of Allergan in March 2015 and the approval of the name change by Actavis shareholders on 5 June; it announced its intention to change names in February. The company's US and Canadian generics business is to retain the Actavis name. CEO and president Brent Saunders said, "By adopting the Allergan name, we are ensuring that our corporate identity reflects the transformation of our company within the pharmaceutical industry and our position as a dynamic new breed of company – a leader in growth pharma." The combination of the two firms has created a new top-10 pharma company by revenues.